bulevirtide
Peptideexperimental
Clinical trial activity
10 trials · 7 clinical orgs · 0 marketing orgs
Phase 1
3
Phase 2
7
Phase 3
3
Phase 4
0
Earliest trial started Mar 1, 2014 (NCT02637999)
Timeline
Indications
Mechanism of action
- Bile acid transporterINHIBITOR
Bile acid transporter inhibitor
Binds and inactivates the NTCP which is the essential viral entry receptor.
Chemistry & pharmacology
- Chirality
- Single Stereoisomer
- Inorganic
- No
- Polymer
- No
- Multi-specific
- No
Oral
No
Parenteral
No
Topical
No
Sources
- ChEMBLCHEMBL4297792 ↗
- ChEMBLCHEMBL4297711 ↗
Also known as
- myrcludex
Clinical trials
| NCT ID | Phase | Start date | Sponsor(s) |
|---|---|---|---|
| NCT07200908 | Phase 3 | Aug 27, 2025 | Bluejay Therapeutics, Inc. |
| NCT07142811 | Phase 2 | Aug 5, 2025 | Vir Biotechnology, Inc. |
| NCT07128550 | Phase 3 | Jul 30, 2025 | Vir Biotechnology, Inc. |
| NCT05765344 | Phase 1 | Mar 15, 2023 | Gilead Sciences |
| NCT05760300 | Phase 1 | Mar 15, 2023 | Gilead Sciences |
| NCT03852719 | Phase 3 | Apr 15, 2019 | Hepatera Ltd., MYR Pharmaceuticals GmbH |
| NCT03852433 | Phase 2 | Apr 15, 2019 | Hepatera Ltd., MYR Pharmaceuticals GmbH |
| NCT03546621 | Phase 2 | Feb 16, 2016 | Data Matrix, LTD, Hepatera Ltd. |
| NCT02637999 | Phase 1/Phase 2 (Phase 2) | Mar 1, 2014 | Hepatera Ltd., Moscow Regional Resarch adn Clinical Institute |
| NCT06780579 | N/A | — | Gilead Sciences |
Showing 10 of 10 trials
Page 1 / 1
Organizations
Research & Development (7)
| Organization | Org type | Trials | As lead sponsor | Phases | Earliest year |
|---|---|---|---|---|---|
| Hepatera Ltd. | For profit | 4 | 2 | 2 | 2014 |
| Gilead Sciences | For profit | 3 | 3 | 2 | 2023 |
| MYR Pharmaceuticals GmbH | For profit | 2 | 2 | 2 | 2019 |
| Vir Biotechnology, Inc. | For profit | 2 | 2 | 2 | 2025 |
| Bluejay Therapeutics, Inc. | For profit | 1 | 1 | 1 | 2025 |
| Data Matrix, LTD | For profit | 1 | 0 | 1 | 2016 |
| Moscow Regional Resarch adn Clinical Institute | Academic/Hospital | 1 | 0 | 1 | 2014 |
7 organizations
Page 1 / 1